Table 5.

Comparison of patients with progression (drop in FVC > 10%, and/or drop in DLCO > 15% or death in followup) with patients with no progression or with improvement.

VariablesPatients with Progression, n = 28 (24%)Patients without Progression or with Improvement, n = 90 (76%)cOR (95% CI), paOR (95% CI), p
Age at baseline evaluation*, mean ± SD57.75 ± 10.4752.43 ± 11.601.04 (1.002–1.08), 0.041.02 (0.97–1.07), 0.34
Male sex8 (28.6)25 (28)1.04 (0.40–2.66), 0.93
Extent of lung disease in HRCT according to Goh score, mean ± SD48.3 ± 18.1950.2 ± 23.30.99 (0.97–1.02), 0.70
Extent of ground glass in HRCT according to Goh score*, mean ± SD37.82 ± 19.6645.51 ± 18.510.97 (0.95–1.002), 0.080.98 (0.95–1.01), 0.42
Extent of fibrosis in HRCT according to Goh score7.2 (2.9–19.2)5.76 (2.64–8.64)1.03 (0.99–1.07), 0.097
Baseline % of DLCO**52.2 ± 26.252 ± 27.71.0002 (0.98–1.01), 0.97
Baseline % of FVC60 (43–81.5)53.3 (42–74)1.009 (0.99–1.02), 0.35
Patients unable to perform DLCO at baseline due to the severity of lung disease**6 (21.5)7 (8)3.23 (0.98–10.60), 0.0535.95 (1.34–26.41), 0.02
UIP HRCT pattern*8 (28.6)7 (8)4.74 (1.53–14.62), 0.0073.45 (0.85–13.99), 0.082
Anti-Jo1 positivity12 (42.8)38 (42.2)1.02 (0.43–2.41), 0.95
Ro52-positive14/28 (56)50/81 (62)0.78 (0.31–1.95), 0.60
Smoking history (current/former)9 (32)35 (39)0.74 (0.30–1.82), 0.52
  • Values are n (%) unless otherwise specified.

  • * Variables with p < 0.15 in the univariate analysis were included in a multivariable logistic regression analysis to adjust for confounding. All possible interactions were evaluated, and none was found.

  • ** Data from 105 patients; 13 patients were unable to perform DLCO because of the severity of lung disease.

  • This variable was not included in the multivariable analysis because of its collinearity with UIP HRCT pattern. FVC: forced vital capacity; cOR: crude OR; aOR: adjusted OR; HRCT: high-resolution computed tomography; UIP: usual interstitial pneumonia.